At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNTX Context Therapeutics Inc.
Pre-Market Trading 11-22 08:14:43 EST
1.50
-0.13
-7.98%
盘前1.40
-0.10-6.67%
08:07 EST
High1.58
Low1.32
Vol589.77K
Open1.53
D1 Closing1.63
Amplitude16.25%
Mkt Cap112.50M
Tradable Cap58.97M
Total Shares75.00M
T/O860.28K
T/O Rate1.50%
Tradable Shares39.31M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Context Therapeutics: A Promising Investment in Innovative Oncology Therapies with Strong Financial Position
BRIEF-Bioatla And Context Therapeutics Announce Exclusive Worldwide License Agreement To Develop And Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Bioatla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize Ba3362, a Nectin-4 X Cd3 T Cell Engaging Antibody
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.